GSK Files NDA For Oncology Anti-Nausea Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Casopitant, follow-on to Zofran, is part of GSK’s larger plan to grow its oncology portfolio in supportive care.
You may also be interested in...
GSK’s Rezonic and Debiovision’s Sanvar To Get Advisory Committee Reviews In May
FDA has been digesting both applications for a considerable amount of time.
GSK’s Rezonic and Debiovision’s Sanvar To Get Advisory Committee Reviews In May
FDA has been digesting both applications for a considerable amount of time.
FDA “Approvable” Letter Requests Validation, Stability Data For Merck’s Emend IV
Firm will respond “within the next few months” to May 3 letter, Merck tells “The Pink Sheet” DAILY.